About ABBV-744 as a potential therapeutic option for aggressive cancers
The present work examined the potential of employing ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in equally p53 wild-type (WT) breast tumor cells and in cells lacking practical p53 either on your own or in combination with tamoxifen, though the effectiveness of ABBV-74